country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-185701

Copy Link Print Information

W-GTF01

W-GTF01 is a MGAT1 inhibitor. W-GTF01 blocks the MGAT1-catalyzed glycosylation of CD73, and inhibits CD73 dimerization, membrane translocation and adenosine production. W-GTF01 restores the function of IFNγ-producing CD8⁺ T cells, enhances tumor infiltration and activation of CD8⁺ T cells, and suppresses tumor growth. W-GTF01 can be used in research related to triple-negative breast cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 951968-89-1
Formel: C₂₄H₂₀N₂O₅
Molecular Weight:416.43

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

W-GTF01 Chemical Structure

CAS. Nr.: 951968-89-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

W-GTF01 restores tumor immune response in immunosuppressive breast cancer cells and reduces CD73 membrane localization in MDA-MB468 and MDA-MB231 triple-negative breast cancer (TNBC) cells by blocking MGAT1-mediated CD73 glycosylation^[1].
W-GTF01 potently and dose-dependently inhibits MGAT1 enzymatic activity via specific binding to the MGAT1 active site^[2].
W-GTF01 revives CD8⁺ effector T cell function (including IFNγ production) and reduces MDA-MB468 TNBC cell survival in a CD73-dependent manner in 2D coculture with PBMCs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

W-GTF01 (5 mg/kg; i.p.; twice per week) sensitizes 4T1-hPD-L1 triple-negative breast cancer tumors to anti-PD-L1 therapy in BALB/C mice, enhancing tumor growth suppression, improving survival, increasing CD8⁺ T cell infiltration and activation, and reducing T cell exhaustion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/C (female; syngeneic triple-negative breast cancer model with 4T1-hPD-L1 cells injected subcutaneously into mammary fat pad)^[2]
Dosage:

5 mg/kg
Administration:

i.p.; twice per week
Result:

Exhibited enhanced tumor growth suppression relative to single treatments.
Prominently improved survival outcomes compared with monotherapy and control groups.
Markedly elevated CD8+ T cell infiltration and activation and mitigated T cell exhaustion versus anti-PD-L1 antibody alone.

Chemical Information

CAS. Nr. 951968-89-1
Molecular Weight 416.43
Formel C₂₄H₂₀N₂O₅
SMILES

O=C(C1=CC(OCO2)=C2C=C1)NC3=CC(C4=NC5=C(C=C(C)C(C)=C5)O4)=C(O)C(C)=C3
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Chi J. MGAT1-Mediated Glycosylation Orchestrates Immune Checkpoints and Antitumor Immunity. Clin Cancer Res. 2025 Jun 15;31:P2-06-12.

[2]. Chi JJ, et al. MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer. Nat Commun. 2025;16(1):3552. Published 2025 Apr 15. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen